|
When
the Cure Is Worse Than the Disease
by
Bill Sardi
by Bill Sardi
DIGG THIS
Mary wonders
why the new young doctor she visited recently says to nearly every
patient, after examining their throat, that it looks like their
esophagus is being eroded by stomach acid and they need to start
taking acid-blocking pills. He hands patients free samples provided
by pharmaceutical companies. The patients are oblivious to the
fact that if they begin using the drug, they may never be able to
stop taking it without experiencing an excruciatingly painful bout
of rebound heartburn.
One way to
build an income in private medical practice is to hook patients
on drugs that continually require re-examination, testing and prescription
renewal.
For example,
blood thinners require prothrombin tests to determine how long it
takes the blood to clot. Blood pressure pills require monitoring
of blood pressure. And in the example above, once patients start
taking acid-blocking medications they will find it is nearly impossible
to stop taking them because withdrawal will provoke rebound acidity
with throat-gripping pain.
Since the early
1990s it has been known that acid-blocking (histamine blocking)
drugs commonly prescribed for heartburn create dependency. Withdrawal
from the drug will create rebound hyper-acidity that causes the
patient to reach for the antacid pills in desperation again.
[1] , [2] To
make matters worse, acid blockers may induce more, not less, disease.
Stomach acid is a defense against invading pathogenic bacteria that
enter the gut in food (foods are not sterile, but have low bacteria
and mold counts that stomach acid normally kills). The habitual
use of acid blockers may result in infection and even cancer. [3]
Most drugs
don’t work, are inappropriate or are designed to make things worse
Critical examination
of the effectiveness of prescription drugs reveals that there is
(1) convincing data that most prescription drugs are not only ineffective
but may worsen the condition being treated (yet are approved by
the FDA), that (2) some of these medications appear to be designed
to create life-long dependency upon the drug (drug withdrawal exacerbates
symptoms), and that (3) some long-standing drugs that are the hallmarks
of modern medicine have begun to lose their biological punch.
There are many
examples of this:
It has recently
been shown that asthma symptoms worsen upon withdrawal of the drug
Accolate (zafirlukast), with benefits lasting only for the first
five weeks and then symptoms return soon thereafter. The FDA approved
this drug based upon short-term use data. Benefits are seen for
only the first five weeks, after which symptoms return to their
original state within seven weeks. Side effects range from diarrhea
to liver damage. With no long-term benefits, the drug is only problematic
for users. [4]
Other asthma
drugs, such as albuterol, ventolin and salbutamol, work in the short
term to relax airways, but over the long term over-sensitize the
body and make the drugs less effective. Then airways become more
sensitive to asthma triggers.
[5]
Quetiapine,
a drug commonly used in nursing homes to treat agitation and related
symptoms in people with Alzheimer’s disease, actually worsens their
condition and speeds the rate of their mental decline.
[6]
First-line
drugs used to treat Alzheimer’s do not stop the progression of the
disease and are largely disappointing,
[7] and side effects caused by second-line treatments (like
Quetiapine) for Alzheimer’s-related psychosis, aggression and agitation,
offset any modest advantages of first-line drugs. [8] Drugs like these ensure your
loved ones will never make it out of the Alzheimer’s care facility.
Diabetes rates
are exploding in America. Millions of Americans are being placed
on anti-diabetic drugs. But nearly all anti-diabetic drugs result
in weight gain and eventual total dependency upon insulin injections. [9] , [10] This is another example of drugs locking
patients into inevitably more severe disease.
Disease
substitution, not disease treatment
All too frequently,
drugs substitute one disease for another. For example, most anti-psychotic
drugs induce weight gain and diabetes.
[11] , [12]
This is so typical that many people believe a pudgy body always
accompanies mental disorders.
Another example
of disease substitution is the treatment of high blood pressure
with diuretics which can induce a vitamin B1 (thiamine) deficiency
that results in heart failure. One study found a third of patients
hospitalized for heart failure, who are often treated with diuretics,
were vitamin B1 deficient. [13] Vitamin therapy is uncommon in hospital
settings.
Blood pressure
drugs: inappropriate treatment
Consider drug
therapy for high blood pressure, what doctors call hypertension.
The idea is to lower blood pressure with medications and reduce
the risk for a stroke. But no single blood pressure pill seems
to work. More than one drug is often needed, and there are few
if any studies that prove combination therapies are safe and effective. [14]
Most blood
pressure drugs do not address the cause of the disease, which commonly
are age-related changes in blood sugar or hardening of the arteries,
resulting in inability of the blood vessels to dilate (widen) upon
physical or mental exertion or stress.
Age-related
inability to control blood sugar levels is generally caused by insulin
resistance (inability of insulin to enter cells) which is induced
by iron overload, [15] ,
[16] , [17]
and hardening of the arteries by calcification which impairs dilation.
Diabetics experience
buildup of underlying calcium in their arteries, which largely explains
diabetic hypertension.
[18]
Calcification
of the inside wall of arteries induces coronary artery disease and
hypertension, which can be measured by a CT scan. [19] Rats that spontaneously develop hypertension exhibit calcified
aortas (the aorta is the first blood vessel outside the heart). [20]
Once the aorta
stiffens due to calcification, then the heart must pump harder against
this resistance, and hypertension develops. Societies that consume
the most calcium have the highest rates of cardiovascular disease.
Presently used calcium blocker drugs are not so satisfactory, but
fortunately nature provides a component in whole grains (IP6 phytate,
bran factor), which dissolves calcifications, but IP6 goes unused
by modern medicine. [21]
The lack of
HDL “good” cholesterol, the alleged cause of artery disease, is
just a marker of arterial calcification. [22] ,
[23]
But instead
of employing agents that will reduce the iron load or calcifications,
like IP6 [24] rice bran, vitamin D, [25] vitamin K [26] or magnesium, [27] other inappropriate medications are used, such as:
-
Beta
blockers, which slow the heart rate to control blood pressure,
but an overly fast heart rate is not the common cause of hypertension.
Beta blockers induce a form of heart failure, cause fatigue
and impotence and breathing problems, another example of disease
substitution.
-
ACE
inhibitors (angiotensin converting enzyme), which are employed
to control blood pressure, but again, hypertension is not commonly
caused by an excess of this enzyme.
-
Diuretics
(water pills), which are prescribed for hypertension, but again,
chronic elevated blood pressure is not caused by too much fluid
in the circulatory system. The depletion of water will artificially
lower blood pressure, but also deplete the body of essential
minerals (electrolytes) required for proper heart rhythm and
deplete vitamin B1 (thiamine) which then induces heart failure
and mental problems, as previously mentioned.
-
Statin
drugs help to lower blood pressure, [30] but not by their ability to reduce cholesterol,
but because they modestly increase vitamin D levels, which is
an anti-calcifying agent.
[31]
Adults at risk
for cardiovascular disease are warned they will experience a heart
attack if they don’t take their cholesterol-lowering drugs. Yet
with millions of Americans taking these drugs, the number of heart
attacks remains about the same. There is simply no evidence that
statin drugs, the most commonly used drug for cholesterol reduction,
reduce mortality rates.
[32]
It is said
statin drugs lower the risk for a heart attack by 30% (relative
number), but in hard numbers the risk reduction is almost imaginary,
with only 1-in 70 high-risk individuals, and in maybe 1-in 300 healthy
individuals, averting a non-mortal heart attack, and these imaginary
benefits are weighed against the real risk for liver damage, memory
loss, muscle damage and other side effects. (Ask yourself how the
FDA could possibly approve such a class of ineffective drugs.)
Paul J. Rosch,
Clinical Professor of Medicine and Psychiatry at New York Medical
College, has recently said:
The belief
that coronary artery atherosclerosis (plaque) is due to high cholesterol
from increased saturated fat intake originated from experiments
in herbivorous animals. It was reinforced by reports allegedly
demonstrating this sequence of events in various populations but
ignoring contradictory data. The idea has been perpetuated by
powerful forces using similar tactics to preserve the profit and
the reputations of those who promote this doctrine. Opponents
find it difficult to publish their scientifically supported opinions.
The advent of statins has further fuelled this fallacious lipid
hypothesis, despite compelling evidence that their effect is not
due to cholesterol lowering and that serious side effects have
been suppressed and alleged benefits have been hyped. The adverse
effects of the cholesterol campaign on health, quality of life,
the economy and medical research are inestimable. It is imperative
that public health officials, physicians and patients are apprised
of proof that it is misguided, malicious and malignant. [33]
This outspoken
opinion was aired in a medical journal published outside the U.S.
Drugs losing
their punch
Add to all
these aforementioned problems with prescription medications the
fact that the “magic bullets” of modern medicine, the antibiotic
drugs, are becoming less and less effective due to germ resistance.
Germs are now developing resistance against vancomycin, the antibiotic
of last resort, which is reserved for use when other antibiotics
fail. Reports are increasing that vancomycin is unable to kill
off Staphylococcus aureus that causes pneumonia, which can be mortal.
[34] An estimated 3355% of Staphylococcus aureus infections
in U.S. hospitals are now resistant to first-line antibiotic therapy.
[35] Repeated use of antibiotics pushes patients to the day
when they will develop an infection and not be able to recover from
it.
In the cancer
treatment arena, resistance to chemotherapy is believed to cause
treatment failure in over 90% of patients with metastatic (spreading)
cancer. [36] One study shows chemotherapy works to produce
5-year survival in less than 3% of cases. [37] Chemotherapy does temporarily
shrink tumors by 50%, but leaves the patient with a totally impaired
immune system. Furthermore, chemotherapy cannot penetrate solid
tumors (breast, prostate, lung, colon, pancreas, brain, liver, etc),
which represent the majority of tumors in humans. Most cancer
patients succumb to side effects caused by treatment before they
do from their tumors.
Summary
The major classes
of prescription drugs are failures. Of concern is the realization
most drugs are never designed to address the underlying biochemical
causes of disease and may intentionally be designed to create life-long
dependency.
Adjectives
that could be used to describe modern pharmacology range from “disappointing,
unacceptable, ineffective,” to “immoral, despicable, shameful,
appalling, wicked, dreadful.” The Food & Drug Adminstration
approval of such drugs gives false credence to medical therapies
that were never designed for cure but rather to keep patients in
a state of chronic disease and drug enslavement. This report begs
for a follow-up report on safe and effective alternatives to prescription
drugs, which is forthcoming.
- Nearly
all anti-diabetic drugs cause a person to become overweight and
totally dependent upon insulin.
- Asthma
drugs sensitize the body to triggers that worsen this condition.
- There is
no evidence that cholesterol-lowering drugs reduce mortality rates.
- All cancer
chemotherapy drugs result in tumor resistance.
- None of
the many drugs prescribed to control high blood pressure address
the cause of hypertension.
- Antacid
“heartburn” drugs induce greater problems when withdrawing from
them, locking patients into lifetime use.
- Of the
many drugs used to treat age-related senility, none stop the progression
of mental decline and some hasten it.
- To an increasing
degree, man-made antibiotics produce germ-resistance and mortality
rates are rising from infections once conquered by these drugs.
References
[1] Nwokolo CU, Smith JT, Rebound
intragastric hyperacidity after abrupt withdrawal of histamine
H2 receptor blockade. Gut 1991 Dec; 32(12):1455-60.
[2] Fullatron GM, Macdonald AM, McColl
KE, Rebound hypersecretion after H2-antagonist withdrawal
a comparative study with nizatidine, ranitidine and famotidine.
Aliment Pharmacological Therapy 1991 Aug; 5(4):391-8.
[3] Waldum HL, Brenna E, Sandvik AK, Long-term safety
of proton pump inhibitors: risks of gastric neoplasia and infections.
Expert Opinion Drug Safety. 2002 May; 1(1):29-38.
[4] Reid DW, Misso NL, Aggarwal S,
Tolerance and rebound with zafirlukast in patients with persistent
asthma. Journal of Negative Results in BioMedicine 2008,
7:3.
[5] Drugs make asthma worse, BBC NEWS: August 17, 2003: McGraw
DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB, Antithetic regulation
by beta-adrenergic receptors of Gq receptor signaling via phospholipase
C underlies the airway beta-agonist paradox. Journal Clinical
Investigation 2003 Aug; 112(4):619-26.
[6] Ballard C, Margallo-Lana M, Juszczak E, et. al., Quetiapine
and rivastigmine and cognitive decline in Alzheimer's disease:
randomised double blind placebo controlled trial. British Medical
Journal 2005 Apr 16; 330(7496):874.
[7] Ringman JM, Cummings JL, Current emerging pharmacological
treatment options for dementia. Behavioral Neurology 2006; 17(1):5-16.
[8] Schneider LS, Tariot PN, Dagerman KS, Effectiveness
of atypical antipsychotic drugs in patients with Alzheimer's disease.
New England Journal Medicine 2006 Oct 12; 355(15):1525-38.
[9] Krentz AJ, Management of type 2 diabetes in the
obese patient: current concerns and emerging therapies. Current
Medical Research Opinion 2008 Feb; 24(2):401-17.
[10] Nichols GA, Gomez-Caminero A, Weight changes
following the initiation of new anti-hyperglycaemic therapies.
Diabetes Obesity Metabolism 2007 Jan; 9(1):96-102.
[11] Ramaswamy K, Masand PS, Nasrallah HA, Do
certain atypical antipsychotics increase the risk of diabetes?
A critical review of 17 pharmacoepidemiologic studies. Annals
Clinical Psychiatry. 2006 Jul-Sep; 18(3):183-94.
[12] Dibben CR, Kalavalapalli SS, Linnington HE,
et. al., Diabetes associated with atypical antipsychotic treatment
may be severe but reversible: case report. International J Psychiatry
Medicine 2005; 35(3):307-11.
[13] Hanninen SA, Darling PB, Sole MJ, Barr A, Keith
ME, The prevalence of thiamin deficiency in hospitalized patients
with congestive heart failure. J American College Cardiology 2006
Jan 17; 47(2):354-61.
[14] Neutel JM, Prescribing patterns in hypertension:
the emerging role of fixed-dose combinations for attaining BP
goals in hypertensive patients. Current Medical Research Opinion
2008 Jul 9.
[15] Sharifi F, Nasab NM, Zadeh HJ, Elevated serum
ferritin concentrations in prediabetic subjects. Diabetes Vascular
Disease Research 2008 Mar; 5(1):15-8.
[16] Tsimihodimos V, Gazi I, Kalaitxidis R, Elisaf
M, Siamopoulos KC, Increased serum ferritin concentrations and
liver enzyme activities in patients with metabolic syndrome. Metab
Syndr Relat Disord. 2006 Fall; 4(3):196-203
[17] Mojiminiyi OA, Marouf R, Abella NA, Body iron
stores in relation to the metabolic syndrome, glycemic control
and complications in female patients with type 2 diabetes. Nutrition
Metabolism Cardiovascular Disease 2007 Dec 4.
[18] Soor GS, Vukin I, Leong SW,
et. al., Peripheral vascular disease: who gets it and why? A histomorphological
analysis of 261 arterial segments from 58 cases. Pathology. 2008
Jun; 40(4):385-91.
[19] Husmann L, Scheffel H, Valenta I, et. al., Impact
of hypertension on the diagnostic accuracy of coronary angiography
with computed tomography. International Journal Cardiovascular
Imaging. 2008 Mar 28
[20] Kanemaru K, Seya K, Miki I, et. al., Calcification
of aortic smooth muscle cells isolated from spontaneously hypertensive
rats. Journal Pharmacology Science 2008 Feb;106(2):280-6.
[21] Seely S, Is calcium excess in western diet a
major cause of arterial disease? International Journal Cardiology
1991 Nov; 33(2):191-8.
[22] Orakzai SH, Nasir K, Blaha M, et. al., Non-HDL
cholesterol is strongly associated with coronary artery calcification
in asymptomatic individuals. Atherosclerosis. 2008 Mar 25.
[23] Allison MA, Wright CM, A comparison of HDL and
LDL cholesterol for prevalent coronary calcification. Int J Cardiol.
2004 May;95(1):55-60.
[24] Grases F, Sanchis P, Perello J, Isern B, Prieto
RM, Fernandez-Palomeque C, Fiol M, Bonnin O, Torres JJ. Phytate
(Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications
in rats. Frontiers Bioscience 2006 Jan 1; 11:136-42.
[25] Grases F, Sanchis P, Perelló J, Isern B, Prieto
RM, Fernández-Palomeque C, Torres JJ. Effect of crystallization
inhibitors on vascular calcifications induced by vitamin D: a
pilot study in Sprague-Dawley rats. Circulation Journal 2007 Jul;
71(7):1152-6.
[26] Jie KS, Bots ML, Vermeer C, Witteman JC, Grobbee
DE. Vitamin K intake and osteocalcin levels in women with and
without aortic atherosclerosis: a population-based study. Atherosclerosis.
1995 Jul; 116(1):117-23.
[27] Rayssiguier Y, Mbega JD, Durlach V, Gueux E,
Durlach J, Giry J, Dalle M, Mazur A, Laurant P, Berthelot A.
Magnesium and blood pressure. I. Animal studies. Magnesium Research
1992 Jun; 5(2):139-46.
[28] Touyz RM. Magnesium supplementation as an adjuvant
to synthetic calcium channel antagonists in the treatment of hypertension.
Medical Hypotheses. 1991 Oct; 36(2):140-1
[29] Touyz RM, Laurant P, Schiffrin EL. Effect of
magnesium on calcium responses to vasopressin in vascular smooth
muscle cells of spontaneously hypertensive rats. J Pharmacology
Experimental Therapeutics 1998 Mar; 284(3):998-1005.
[30] Kjeldsen SE, Jamerson KA, Bakris GL, Predictors
of blood pressure response to intensified and fixed combination
treatment of hypertension: the ACCOMPLISH study. Blood Pressure
2008;17(1):7-17.
[31] Pérez-Castrillón JL, Vega G, Abad L, Sanz A,
Chaves J, Hernandez G, Dueñas A. Effects of Atorvastatin on vitamin
D levels in patients with acute ischemic heart disease. American
Journal Cardiology 2007 Apr 1;99(7):903-5.
[32] Abramson J, Wright J (2007). "Are lipid-lowering
guidelines evidence-based?" Lancet 369 (9557): 168-9.
[33] Rosch PJ, Cholesterol does not cause coronary
heart disease in contrast to stress. Scandinavian Cardiovascular
Journal 2008 Apr 1:1-6.
[34] Sakoulas G , Moellering RC Jr, Increasing
antibiotic resistance among methicillin-resistant Staphylococcus
aureus strains. Clinical Infectious Disease 2008 Jun 1; 46 Suppl
5:S360-7.
[35] Appelbaum PC, MRSA the tip of the iceberg. Clinical
Microbiology Infection 2006 Apr;12 Suppl 2:3-10.
[36] Longley DB, Johnston PG, Molecular mechanisms of drug
resistance. Journal Pathology 2005 Jan; 205(2):275-92.
[37] Morgan G, Ward R, Barton M. The contribution of cytotoxic
chemotherapy to 5-year survival in adult malignancies. Clinical
Oncology 2004; 16:549-60.
August
25, 2008
Bill
Sardi [send
him mail] is a frequent writer on health and political
topics. His health writings can be found at www.naturalhealthlibrarian.com.
He is the author of You
Don’t Have To Be Afraid Of Cancer Anymore.
Copyright
© 2008 Bill Sardi Word of Knowledge Agency, San Dimas, California.
This article has been written exclusively for www.LewRockwell.com
and other parties who wish to refer to it should request permission
to link rather than posting at other URLs.
Bill
Sardi Archives
|